Department of Medicine, Division of Hematology/Oncology, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Division of Hematology/Oncology, Lifespan Cancer Institute, Providence, RI 02903, USA.
Future Oncol. 2018 Aug;14(19):1965-1976. doi: 10.2217/fon-2017-0722. Epub 2018 Jul 18.
The therapeutic armamentarium for multiple myeloma has grown significantly over the past decade. We characterized ongoing multiple myeloma clinical trials utilizing ClinicalTrials.gov . A search of ClinicalTrials.gov on 21 April 2017 returned 239 therapeutic interventional trials in multiple myeloma. A majority (84.1%) of trials are early-phase (I/II). Immunotherapies are significantly more likely to be studied in Phase I trials than Phase II trials (p = 0.0049). Primary sponsor (academic, cooperative group, industry) is significantly associated with phase of trial (p = 0.0334). Quality of life assessment is included as a secondary objective in only 10.1% of trials. Areas of need are continued advancement of immunotherapies, late-phase studies utilizing a triplet control group, and an objective focus on quality of life.
过去十年中，多发性骨髓瘤的治疗方法有了显著的发展。我们利用 ClinicalTrials.gov 对正在进行的多发性骨髓瘤临床试验进行了描述。2017 年 4 月 21 日，在 ClinicalTrials.gov 上进行了搜索，共返回 239 项多发性骨髓瘤治疗干预试验。大多数（84.1%）试验处于早期阶段（I/II 期）。与 II 期试验相比，免疫疗法更有可能在 I 期试验中进行研究（p=0.0049）。主要赞助商（学术机构、合作组、工业界）与试验阶段显著相关（p=0.0334）。仅 10.1%的试验将生活质量评估作为次要目标。需要继续推进免疫疗法的发展，开展采用三联对照组的后期研究，并将重点放在生活质量上。
